The AstraZeneca drug Imfinzi (durvalumab) has been approved in Canada as of Nov 3, 2017 for the treatment of patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant)Read more
Blog
Dr. Michael A.S. Jewett (University of Toronto and Princess Margaret Cancer Centre) will receive the Exceptional Leadership in Patient Involvement in Cancer award for his long-standing commitment to and advocacy for greater patient involvement in clinical research prioritization, research proposals, funding decisions, research design, and patient-relevant outcome measures, and his championing of patient-led charities as a mechanism toRead more
As part of its mission, Bladder Cancer Canada (BCC) is committed to furthering research into the prevention, diagnosis and treatment of bladder cancer. Thanks primarily to funds raised from the annual Awareness Walk, BCC has been able to award $50,000 for two years in a row to research investigators committed to improving the understanding andRead more
Each year, the Canadian International Freight Forwarders Association (CIFFA) awards the Donna Letterio Leadership Award in memory of former CIFFA President Donna Letterio, who passed away in August 2013. The award recognizes a woman in the global freight logistics sector who has demonstrated, as Donna did, professionalism, commitment, leadership and a passion for excellence in her careerRead more
This year, Bladder Cancer Canada (BCC) is co-funding a $50,000 grant for bladder cancer research in partnership with the Canadian Urological Association Scholarship Foundation (CUASF). The CUASF is a scholarship fund that was set up by the Canadian Urological Association and its Members, and has a long and successful history. Both recipients of this year’s grant areRead more
Photo credit: John Packman Bladder Cancer Canada’s co-founders, Jack Moon and David Guttman, have been named recipients of the Meritorious Service Medal (MSM). This is a high-level and prestigious award which is given with great discretion. It enables the Governor General, on behalf of all Canadians, to honour those who have performed a deed or activity inRead more
In 2016 Bladder Cancer Canada funded the first study to comprehensively produce quality indicators for bladder cancer. Over time these benchmarks will provide the opportunity to improve consistency of care and better outcomes for patients. Though developed in Canada, these indicators can potentially be used around the world. Read the overview below: Read more
